Cargando…

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma

BACKGROUND: Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of these patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shouzheng, Xie, Tongji, Hao, Xuezhi, Wang, Yan, Hu, Xingsheng, Wang, Lin, Li, Yan, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487822/
https://www.ncbi.nlm.nih.gov/pubmed/34490724
http://dx.doi.org/10.1111/1759-7714.14144
_version_ 1784578034047647744
author Wang, Shouzheng
Xie, Tongji
Hao, Xuezhi
Wang, Yan
Hu, Xingsheng
Wang, Lin
Li, Yan
Li, Junling
Xing, Puyuan
author_facet Wang, Shouzheng
Xie, Tongji
Hao, Xuezhi
Wang, Yan
Hu, Xingsheng
Wang, Lin
Li, Yan
Li, Junling
Xing, Puyuan
author_sort Wang, Shouzheng
collection PubMed
description BACKGROUND: Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of these patients and explore the treatment modes after transformation. METHODS: EGFR‐mutant LADC patients with SCLC transformation were retrospectively included in the study. Demographic and clinical data were collected. Survival outcomes and corresponding influential factors were analyzed. RESULTS: Twenty‐nine patients were included in the study. The median progression‐free survival (PFS) of patients who received first‐line EGFR‐TKIs was 13.1 months. The median time to SCLC transformation was 27.5 months. After transformation, the objective response rates of patients who received first‐line chemotherapy with or without EGFR‐TKIs were 43.8% and 37.5%, respectively. The median PFS of patients reveiving chemotherapy with EGFR‐TKIs was significantly longer than that of patients receiving chemotherapy without EGFR‐TKIs (5.2 vs. 3.0 months; HR, 0.19; 95% CI: 0.05–0.72; p = 0.014). However, there was no significant difference in median overall survival (OS) between patients who received chemotherapy with or without EGFR‐TKIs (14.8 vs. 13.0 months; p = 0.474). In the multivariate Cox proportional hazards regression analysis, both anti‐angiogenic treatment (HR, 0.04; 95% CI: 0.01–0.29; p = 0.001) and local radiotherapy (HR, 0.28; 95% CI: 0.08–0.97; p = 0.044) were significantly associated with better patient OS after transformation. CONCLUSIONS: Compared with chemotherapy alone, the combination of chemotherapy and EGFR‐TKIs as first‐line treatment after SCLC transformation can benefit patients in PFS but not in OS. However, anti‐angiogenic therapies and local radiotherapy can significantly prolong OS after transformation.
format Online
Article
Text
id pubmed-8487822
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-84878222021-10-08 Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma Wang, Shouzheng Xie, Tongji Hao, Xuezhi Wang, Yan Hu, Xingsheng Wang, Lin Li, Yan Li, Junling Xing, Puyuan Thorac Cancer Original Articles BACKGROUND: Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of these patients and explore the treatment modes after transformation. METHODS: EGFR‐mutant LADC patients with SCLC transformation were retrospectively included in the study. Demographic and clinical data were collected. Survival outcomes and corresponding influential factors were analyzed. RESULTS: Twenty‐nine patients were included in the study. The median progression‐free survival (PFS) of patients who received first‐line EGFR‐TKIs was 13.1 months. The median time to SCLC transformation was 27.5 months. After transformation, the objective response rates of patients who received first‐line chemotherapy with or without EGFR‐TKIs were 43.8% and 37.5%, respectively. The median PFS of patients reveiving chemotherapy with EGFR‐TKIs was significantly longer than that of patients receiving chemotherapy without EGFR‐TKIs (5.2 vs. 3.0 months; HR, 0.19; 95% CI: 0.05–0.72; p = 0.014). However, there was no significant difference in median overall survival (OS) between patients who received chemotherapy with or without EGFR‐TKIs (14.8 vs. 13.0 months; p = 0.474). In the multivariate Cox proportional hazards regression analysis, both anti‐angiogenic treatment (HR, 0.04; 95% CI: 0.01–0.29; p = 0.001) and local radiotherapy (HR, 0.28; 95% CI: 0.08–0.97; p = 0.044) were significantly associated with better patient OS after transformation. CONCLUSIONS: Compared with chemotherapy alone, the combination of chemotherapy and EGFR‐TKIs as first‐line treatment after SCLC transformation can benefit patients in PFS but not in OS. However, anti‐angiogenic therapies and local radiotherapy can significantly prolong OS after transformation. John Wiley & Sons Australia, Ltd 2021-09-06 2021-10 /pmc/articles/PMC8487822/ /pubmed/34490724 http://dx.doi.org/10.1111/1759-7714.14144 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Wang, Shouzheng
Xie, Tongji
Hao, Xuezhi
Wang, Yan
Hu, Xingsheng
Wang, Lin
Li, Yan
Li, Junling
Xing, Puyuan
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
title Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
title_full Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
title_fullStr Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
title_full_unstemmed Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
title_short Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
title_sort comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487822/
https://www.ncbi.nlm.nih.gov/pubmed/34490724
http://dx.doi.org/10.1111/1759-7714.14144
work_keys_str_mv AT wangshouzheng comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT xietongji comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT haoxuezhi comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT wangyan comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT huxingsheng comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT wanglin comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT liyan comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT lijunling comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma
AT xingpuyuan comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma